Rhythm Pharmaceuticals, Inc.
RYTM
$96.22
-$1.70-1.74%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.50M | 32.70M | 41.83M | 33.25M | 29.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.50M | 32.70M | 41.83M | 33.25M | 29.08M |
| Cost of Revenue | 5.54M | 3.65M | 3.79M | 3.83M | 2.95M |
| Gross Profit | 42.96M | 29.06M | 38.04M | 29.42M | 26.13M |
| SG&A Expenses | 45.95M | 39.09M | 38.13M | 35.38M | 36.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.80M | 79.71M | 83.09M | 77.14M | 69.56M |
| Operating Income | -45.30M | -47.00M | -41.26M | -43.89M | -40.48M |
| Income Before Tax | -46.30M | -49.42M | -43.38M | -43.99M | -31.78M |
| Income Tax Expenses | 337.00K | 80.00K | -90.00K | -344.00K | 479.00K |
| Earnings from Continuing Operations | -46.63M | -49.50M | -43.29M | -43.64M | -32.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.63M | -49.50M | -43.29M | -43.64M | -32.26M |
| EBIT | -45.30M | -47.00M | -41.26M | -43.89M | -40.48M |
| EBITDA | -44.92M | -46.62M | -40.87M | -43.50M | -40.09M |
| EPS Basic | -0.75 | -0.81 | -0.72 | -0.73 | -0.55 |
| Normalized Basic EPS | -0.45 | -0.49 | -0.44 | -0.45 | -0.42 |
| EPS Diluted | -0.75 | -0.81 | -0.72 | -0.73 | -0.55 |
| Normalized Diluted EPS | -0.45 | -0.49 | -0.44 | -0.45 | -0.42 |
| Average Basic Shares Outstanding | 63.68M | 63.06M | 61.60M | 61.22M | 61.01M |
| Average Diluted Shares Outstanding | 63.68M | 63.06M | 61.60M | 61.22M | 61.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |